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The field of primary headaches and cranial neuralgias has experienced in a relatively brief period 
a startling progress in expansion of knowledge (1, 2). This has allowed partial unraveling of the 
machinery involved in the occurrence of attacks and the identification of a set of mediators and 
genes that are likely to play a role. In the case of migraine, accumulated evidence has very recently 
led to the development of the first disease-specific prophylactic drug, the CGRP antibodies (3). 
In other cases, drugs available for indications different from pain, such as botulinum toxin or the 
antiepileptic drugs, have been tested with adapted protocols proving effective in chronic migraine 
and showing potential efficacy in other cranial pains, i.e., cluster headache, trigeminal neuralgia, and 
temporomandibular joint disorder (4, 5).
Notwithstanding the undeniable scientific advances, much research is still needed to fully under-
stand and effectively treat primary headaches and cranial neuralgias. Open issues are manifold, span-
ning from pathophysiology to clinical aspects, and represent exciting challenges for future research.
the challenGe OF pathOphySiOlOGical cOMpOnentS 
OF cranial pain
the anatomy
The trigeminovascular system has been implicated as the major sensory system that mediates 
primary and secondary headaches of intracranial origin. More recent is the discovery that sensory 
innervation of the calvarial periosteum overlying the dorsal parts of the frontal and parietal calva-
rial bones is supplied primarily by trigeminal neurons with cell bodies located mainly within the 
ophthalmic division of the trigeminal ganglion (6). Taken together with the limited knowledge about 
the functional anatomy of the neurovascular unit, these data call for more investigations aimed at 
unraveling the functional anatomy and the physiology of cranial pain.
the Genes
Genetic studies have contributed significantly to the current understanding of the molecular patho-
physiology of hemiplegic migraine as a channelopathy. Beyond and besides channelopathies, several 
genetic variants, regulating different functions, with higher frequency and lower effect have been 
implicated in the most common forms of migraine (7). Evidence continues to accumulate from 
association studies for the involvement of the originally suspected vascular system dysregulation, 
for a modified inflammatory state, and for the susceptibility to migraine lying at the intersection of 
increased ascending nociceptive signaling and reduced descending inhibition (8). Migraine stands 
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at the cross road of these functional pathways, with a genetic 
variability that is consistent with the well-known heterogeneous 
nature of this disorder.
the receptors
Identification and cloning of nociceptive receptors has tremen-
dously advanced our understanding of the biology of nociception 
and multimodal pain sensation (9). In-depth characterization of 
functional properties of these receptors, as well as their variable 
expression in different tissues and cell types within the nervous 
system, will prompt the possibility to transfer acquired knowledge 
into clinically relevant advances.
the ictal nature
Most primary headaches, in analogy to cranial neuralgias, are 
chronic conditions, recurring for years/decades, but manifesting 
with episodic flares during which normally functioning indi-
viduals suddenly become very sick and disabled. It is of course 
paramount to keep investigating the mechanisms that trigger the 
sickness, but it seems even more important to decipher the self-
healing mechanisms. Indeed, the capability to recover functional 
integrity after a variable amount of time (minutes, hours, or a 
few days) points to the existence of endogenous mechanisms that 
are highly effective in reinstating homeostasis, to suggest that the 
machinery for controlling the disorder is intrinsically preserved 
in these patients, just temporarily disrupted. Focusing our efforts 
on the clarification and the potentiation of the mechanisms that 
restore normality will prompt additional therapeutic targets and 
options for treating these disorders, in addition to striving to 
prevent the initiation of the attack.
Unveiling these aspects will not only improve understanding 
and management of episodic headache and neuralgia, but it 
will also greatly benefit the prevention of those headaches that, 
episodic in nature, are at higher risk of progressively becoming 
chronic (10). This is mostly observed in some types of primary 
headache, but the phenomenology does not spare secondary 
headaches (i.e., post-traumatic headache, cervicogenic headache, 
TMJ dysfunction) and neuralgias.
the challenGe OF SeX diFFerenceS
It is well established that the majority of primary headaches and 
other trigeminal nerve-associated disorders have higher preva-
lence in females than in males (11, 12). Migraine has a twofold to 
threefold increase in prevalence in women as compared to men, 
and women experience longer duration of attacks, increased risk 
of attack recurrence, greater disability, and a longer period of time 
required to recover (11). There is evidence implicating the role of 
female sex hormones as a major factor in determining migraine 
risk and characteristics, which accounts for sex differences: 
emerging data suggest a sex-driven differential activation of 
inflammatory pathways (13, 14) and support underlying genetic 
variance of specific genes, i.e., estrogen receptor 1 gene (8).
Besides biological factors, psychosocial processes, such as pain 
coping and early-life exposure to stressful events, may also explain 
sex differences in pain (15). Therefore, the future directions of 
research should aim at further elucidating mechanisms that may 
inform efforts to develop sex-specific treatments. In this frame, 
an additional area of interest is represented by the mechanisms 
that influence age-related changes in gender segregation of some 
painful conditions of the head.
the challenGe OF BehaViOral 
aSpectS
Psychobiological events, together with cognitive modulation 
and reward processing have been implicated in chronic orofacial 
pain, including chronic migraine, trigeminal neuropathic pain, 
and pain related to temporomandibular joint disorders (16, 17). 
Scientific knowledge is quite rudimental in this regard, and more 
attention should be focused on the behavioral aspects of pain and 
pain management. Advances in this field will not only provide an 
important improvement in the understanding of headache pain 
but also prompt more specific therapeutic modalities.
the challenGeS in the clinical Field
In the clinical field, challenges involve the need to build more 
evidence in ad hoc controlled studies to prompt the possibility 
to create and implement specific guidelines for the diagnosis 
and management of headaches and head pain. A paradigmatic 
case is represented by medication overuse headache, a secondary 
headache usually presenting in migraineurs in association with 
the excessive use of acute drugs. The condition is treatable but 
an evidence-based consensus on the management is missing. Is 
detoxification from overused drugs necessary? Is the association 
of detoxification plus prophylactic treatment more effective than 
either modality alone? Another example is represented by the 
nosographic framing of trigeminal neuralgia, which is undergo-
ing dynamic shaping among experts (18, 19).
Evidence-based data are also needed to optimize treatment 
in terms of selection of drugs with the best efficacy/tolerability 
profile for a specific patient, to define duration of prophylactic 
cycles, and to identify subpopulations at risk of disease progres-
sion toward a negative outcome.
Finally, but not less important, a challenge that is transversal 
to all chronic disorders is represented by the development and 
implementation of informatic tools and services aimed at facili-
tating the remote management of these patients, which is likely 
to improve the quality of care and the outcome of disease (20).
the challenGe OF diFFerenceS  
that enliGhten
Finally, but no less importantly, because in itself it justifies the 
existence of this section of Frontiers in Neurology, the utmost 
challenge is the clarification of similarities and differences 
between migraine and cranial neuropathic pain. Their patho-
physiological backgrounds involve several similar mechanisms 
(21). Peripheral sensitization occurs in neurons located in the 
dorsal root ganglion or in the trigeminal ganglion, while central 
sensitization appears in the second-order neurons in the dorsal 
horn of the spinal cord or the trigeminal nucleus caudalis. 
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Central neuronal hyperexcitability has been implicated in both 
disorders, as are alterations in the glutamatergic neurotrans-
mission and activation of N-methyl-d-aspartate-receptors, 
according to increasing evidence. Furthermore, migraine and 
neuropathic pain share some clinical features, such as enhanced 
sensitivity to sensory stimuli and cutaneous allodynia. The 
pharmacotherapy of both diseases is often challenging, but both 
respond to antiepileptic drugs (22). Building on these similari-
ties, and unraveling the specific differences, might prompt novel 
candidates for the development of future drugs, hopefully more 
efficacious. The process has already started with the metabolites 
of the kynurenine pathway, for their capability of influencing the 
glutamate receptors (23).
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